The Trump administration had said it would disclose by Wednesday the target prices for drugs, but pharma companies are still ...

Novavax NVAX announced encouraging results from an initial cohort of a late-stage study evaluating its experimental COVID-19-influenza combination (CIC) and stand-alone influenza vaccine candidates.

After soaring to success in the early days of the COVID-19 pandemic, Moderna (NASDAQ: MRNA) experienced a reversal of fortune ...

US Health Secretary Robert F. Kennedy Jr.'s dismissal of a key panel that advises on immunizations policy is a significant ...

His latest action confirms his intention to delist specific vaccines, making them less affordable.

A new COVID variant - NB 1.8.1 - is in New Jersey. Parents can take steps to protect their children from COVID this summer.

The Food and Drug Administration (FDA) has approved Moderna’s next-generation mRNA COVID-19 vaccine mNexspike ®.

The Trump administration is waging war against mRNA vaccines despite President Donald Trump having called them the “gold standard” when his admin rolled out the COVID shots […] ...

The Trump administration's cancellation of $766 million in contracts to develop mRNA vaccines against potential pandemic flu ...

A large prospective cohort study in Germany found no statistically significant increase in major birth defects following ...

(HealthDay News) — The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused by severe acute respiratory syndrome coronavirus 2.

The recent downturn in biotech has battered Massachusetts’ world-renowned sector, and the political climate has only made it ...